ArticleJournal of atherosclerosis and thrombosis2026
Serum ADAMTS18 Levels at Admission Are Associated With 3-Month Functional Outcome After Acute Ischemic Stroke.
Article in Journal of atherosclerosis and thrombosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsADAMTS18 is a secreted metalloproteinase implicated in vascular homeostasis and protection against ischemic brain injury. However, its clinical relevance in acute ischemic stroke (AIS) remains unclear.
methodsWe retrospectively analyzed 194 AIS patients from the Chengdu Stroke Registry. Serum ADAMTS18 levels were measured within 48 hours of admission using ELISA. Associations between ADAMTS18 levels and 3-month poor outcomes (modified Rankin Scale score 3-6) were evaluated using logistic regression. Predictive performance was assessed using area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
resultsAmong 194 patients, the median ADAMTS18 was 21.45 ng/mL (IQR 19.68-23.58 ng/mL), 79 (40.7%) had poor outcomes. Patients with poor outcomes had lower serum ADAMTS18 levels [19.84 (18.46-21.24) vs. 22.88 (21.14-24.81) ng/mL, P＜0.001]. After adjustment, lower ADAMTS18 levels were independently associated with poor outcome (OR 0.70, 95% CI 0.58-0.83, P＜0.001). Quartile analysis showed that compared with the lowest quartile, patients in Q3 (OR = 0.26; 95% CI: 0.08-0.83; P = 0.023) and Q4 (OR = 0.02; 95% CI: 0.00-0.11; P＜0.001) had progressively lower odds of poor functional outcome (P for trend ＜0.001). Restricted cubic spline analysis confirmed a negative linear association (adjusted P
conclusionLower admission ADAMTS18 levels are independently associated with poor 3-month functional outcomes after AIS and may provide additional prognostic information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.